|
市場調查報告書
藥品開發新對策：進化中的R&D效率改善對策
New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
| 出版商 |
Datamonitor |
| 出版日期 |
2009年05月 |
商品編碼 |
90340 |
| 內容資訊 |
英文 79 pages |
| 價格 |
|
|
藥品開發新對策：進化中的R&D效率改善對策 是由出版商Datamonitor在2009年05月所出版的。
這份英文市場調查報告書包含79 pages 價格從美金5700起跳。
產業重整、經濟低迷、不斷增強的非專利藥品的威脅及對製藥公司而言日益高漲的壓力都使得開發各種新藥產品線成為當務之急，但新藥開發也帶來成本負擔及風險。但藥品產業仍努力追求效率和成果，尋找整備R&D流程的新方法。
本報告書內容包括：新藥開發方法進化、產業現況及未來分析。內容綱要摘記如下：
實施概要
現在的R&D情勢概要
- 阻礙R&D最佳化的障礙
- 各製藥企業的R&D改善方法
- 競爭企業彼此合作R&D
- 製藥產業中的2大改善業務方法
- 將R&D資源集中在生物製劑上能有效提昇效率
MEDTRACK的產品線藥及合約資料庫分析
- 藥物產品線數量增加的同時，銷售活動卻減少
- 早期階段的共同開發合約是最普遍的交易形式
參考文獻一覧
附錄
圖表
Abstract
Introduction
With industry consolidation, the economic downturn, and an increasing threat
from generics, pharma companies are coming under greater pressure to fill
their pipelines with innovative drugs. However, despite the costs and risks
involved in drug development, the pharma industry is finding new ways to
streamline the R&D process in an effort to increase efficiency and output.
Scope of this research
- Overview of ongoing trends affecting R&D and how these will shape Pharma
in the future
- R&D Insight from Big Pharma industry executives
- Analysis into Pharma' s evolving R&D portfolio between 2006 and 2009, in
addition to examination of pipeline M&A and collaborative deals
- Case studies of innovative strategies used to maximize R&D productivity
Research and analysis highlights
GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and
clinical drug pipelines, each with approximately 200 candidates in development
as of March 2009. In terms of volume growth Genentech' s pipeline grew the most
in terms of percentage points, almost doubling (up 95%).
Over the period 200609, the average growth per therapy area was 9.4%. In terms
of percentage points, the therapy area experiencing the largest growth in
pipeline candidates was ophthalmology, while cardiovascular pipelines saw the
largest decline, indicative of Pharma' s shift towards niche markets and
personalized medicines.
The number of pipeline deals made during 200608 have steadily declined.
However, with Biotech finding it hard to fund R&D at present, and with many
companies going bankrupt, this will affect Big Pharma in the longer term,
which is increasingly downsizing internal research becoming ever reliant on
external sources.
Key reasons to purchase this research
- Identify R&D trends in today' s pharmaceutical market, and how these affect
productivity and return on investment
- Understand how a diverse range of strategies can improve R&D productivity
and output, and identify how these can best be implemented
- Gain insight into how to optimize R&D processes and increase the chance of
clinical, and ultimately commercial success
Table of Contents
EXECUTIVE SUMMARY
- Scope of the report
- Methodology for primary and secondary research
- Primary research
- Secondary research
- Key findings
OVERVIEW OF TODAY' S R&D LANDSCAPE
- Current barriers to R&D optimization
- How are pharma companies improving R&D?
- Rivals move to collaborate on R&D
- Two key types of restructuring are available to Pharma
- Refocusing R&D onto biologics will increase efficiency
ANALYSIS OF MEDTRACK PIPELINE AND DEALS DATABASES
- Product pipelines grow while deal making activity declines
- Analysis of pipeline candidates by therapy area and indication indicate an
increased focus on niche markets
- The "big four" tumors are the most popular indications for solid tumors
- Antibacterial, antifungal and antiviral pipelines all demonstrate strong
growth
- CNS continues to be a thriving market despite generic competition
- Low levels of innovation hampers the growth of the cardiovascular market
- Ophthalmology had the largest percentage increase in number of drug
candidates in clinical development
- Substance abuse saw a steep rise in Phase I drugs, but a decline in
other stages of development
- Genentech and Bristol-Myers Squibb have shown a significant jump in
pipeline candidates
- Wyeth, GlaxoSmithKline and Johnson & Johnson saw a decline in their
number of pipeline candidates
- Daiichi Sankyo boosts its early-stage pipeline through externalizations
- Recent mergers will sharpen R&D structure
- Early-stage co-development deals remain the most popular deal type
- Early-stage partnerships are the most popular R&D deal type, but have
also seen the steepest decline in recent years
- Co-development deals are most common among earlier-stage companies as
well as the top 50 pharma companies
BIBLIOGRAPHY
- Publications and online articles
- Datamonitor resources
TABLES
- Table: Most popular targets in for drugs in development, 2009
FIGURES
- Figure: The R&D process is failing somewhere between initial innovation
and market approval
- Figure: Reasons why pipeline drug candidates are dropped, 2009
- Figure: Niche, specialty care markets offer Pharma the greatest growth
potential
- Figure: Restructuring Big Pharma R&D operations to increase productivity
- Figure: Biologics will sharpen the focus of the R&D pipeline
- Figure: Biologics are changing the emphasis of the value chain
- Figure: The greatest number of pipeline candidates are in preclinical and
Phase II development, this corresponds to the stages showing the greatest deal
activity, 2006 - Q1 2009
- Figure: Number of US licensing deals valued at $0 - 50m entered into by
the top 20 pharma companies, Q1 2006 - Q3 2008
- Figure: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
- Figure: Pipeline candidates by therapy area and indication, 2006 - Q1 2009
- Figure: Change in number of pipeline deals by therapy area, 2008 versus
2006
- Figure: Number of pipeline candidates versus deals according to therapy
area, 2006 - Q1 2009
- Figure: Level of R&D interest and unmet need for four solid tumors, 2008
- Figure: Clinical unmet needs for the main cardiovascular indications
- Figure: Vaccines have high entry barriers for generic companies
- Figure: Number of pipeline candidates (preclinical and Phase I - III) and
number of deals for the top 10 pharma companies, 2006 - Q1 2009
- Figure: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
- Figure: Origins of Bristol-Myers Squibb' s product portfolio (2008) and
selected key products
- Figure: How externalization is supplementing Daiichi Sankyo' s oncology
pipeline
- Figure: Pfizer, Wyeth and combined Pfizer-Wyeth molecule type and therapy
area configurations (% of Rx sales), 2008
- Figure: Merck & Co, Schering-Plough and combined Merck-Schering-Plough
molecule type configuration (% of Rx sales), 2008
- Figure: Trends in sources and partners for pipeline drug deals in the
pharma industry, 2006 - 08
- Figure: Trends in the source: partner mix for pipeline drug deal-making,
2006 - 08
- Figure: The most common pipeline deal types (2006 - 08) have been
co-development deals although these are now declining
- Figure: Top 10 pipeline drug deal types by partner: source mix, 2006 - 08
- Figure: Trends in number of pipeline candidates according to development
stage, 2006 - Q1 09
- Figure: Trends in number of deals according to development stage, 2006 - 08
|
